Olema Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $157.7M | $124.5M | $86.1M | $82.3M | $51.1M |
| Operating expenses | $178.7M | $142.3M | $105.0M | $107.0M | $71.5M |
| Operating income | -$178.7M | -$142.3M | -$105.0M | -$107.0M | -$71.5M |
| Pretax income | -$162.4M | -$129.5M | — | — | — |
| Income tax expense | $3,000 | $2,000 | $2,000 | $1,000 | — |
| Net income | -$162.5M | -$129.5M | -$96.7M | -$104.8M | -$71.1M |
| Balance Sheet | |||||
| Cash and equivalents | $48.3M | $139.5M | $68.5M | $23.7M | $13.8M |
| Current assets | $515.5M | $438.5M | $266.5M | $208.9M | $290.7M |
| Total assets | $533.4M | $451.0M | $276.9M | $215.6M | $295.9M |
| Current liabilities | $51.8M | $41.8M | $21.6M | $16.5M | $9.0M |
| Total liabilities | $54.9M | $42.0M | $23.1M | $18.1M | $11.4M |
| Stockholders' equity | $478.6M | $409.0M | $253.9M | $197.5M | $284.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$146.7M | -$104.4M | -$83.7M | -$82.1M | -$50.7M |
| Depreciation and amortization | $490,000 | $393,000 | $377,000 | $357,000 | $163,000 |
| Stock-based compensation | $17.6M | $22.6M | $17.3M | $18.8M | $15.9M |
| Capital expenditure | — | $159,000 | — | $363,000 | $1.6M |
| Free cash flow | — | -$104.5M | — | -$82.4M | -$52.3M |
Shares outstanding 87.3M · Free float 63.0%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.